Low-dose aspirin initiated ≤16 weeks of gestation significantly reduced the risk of preterm preeclampsia (RR 0.11; 95% CI 0.04-0.33) but had no significant effect on term preeclampsia.
Meta-Analysis (n=556)
Does low-dose aspirin initiated at or before 16 weeks of gestation reduce the risk of preterm and term preeclampsia in pregnant women?
Early administration of low-dose aspirin at or before 16 weeks of gestation significantly reduces the risk of preterm preeclampsia, though it does not affect the risk of term preeclampsia.
Relative Risk: 0.11 (95% CI 0.04–0.33)
OBJECTIVE: To compare the effect of early administration of aspirin on the risk of preterm and term preeclampsia. METHOD: A systematic review and meta-analysis of randomized controlled trials were performed. Women who were randomized to low-dose aspirin or placebo/no treatment at or before 16 weeks of gestation were included. The outcomes of interest were preterm preeclampsia (delivery <37 weeks) and term preeclampsia. Pooled relative risks (RR) with their 95% confidence intervals (CI) were computed. RESULTS: The search identified 7,941 citations but only five trials on a combined total of 556 women fulfilled the inclusion criteria. When compared to controls, aspirin initiated ≤16 weeks of gestation was associated with a major reduction of the risk of preterm preeclampsia (RR 0.11, 95% CI 0.04-0.33) but had no significant effect on term preeclampsia (RR 0.98, 95% CI 0.42-2.33). CONCLUSION: Low-dose aspirin administrated at or before 16 weeks of gestation reduces the risk of preterm but not term preeclampsia.
Roberge et al. (2012) conducted a meta-analysis in Preeclampsia (n=556). Low-dose aspirin vs. placebo/no treatment was evaluated on preterm preeclampsia (delivery <37 weeks) (RR 0.11, 95% CI 0.04-0.33). Low-dose aspirin initiated ≤16 weeks of gestation significantly reduced the risk of preterm preeclampsia (RR 0.11; 95% CI 0.04-0.33) but had no significant effect on term preeclampsia.